Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets innovative prescription drugs used to treat a number of diseases and conditions, including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease and respiratory. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 121,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... (PRWEB) October 02, 2014 Permian Plastics, ... in the St. Louis, Missouri, area on October 24th, ... become a leading plastic injection molder in the Midwest. ... and is a supplier to many Fortune 500 clients. ... support every step of the way, from concept to ...
(Date:10/2/2014)... The National Institutes of Health (NIH) ... today to develop an electrode array system that ... brain works through unprecedented resolution and scale. , ... to support President Obama's BRAIN (Brain Research through ... to revolutionize our understanding of the human mind ...
(Date:10/2/2014)... octubre de 2014 Laborie Medical Technologies, Inc. ... , ha completado la adquisición de Unisensor AG y ... su sede central sita en Wiesendangen, Suiza, y lleva ... Portsmouth, New Hampshire . Unisensor está especializada en ... resolución para evaluar la presión y valores de pH ...
(Date:10/2/2014)...  NKT Therapeutics today announced that the U.S. ... designation to NKTT120, the company,s lead therapeutic being ... NKTT120 is a humanized monoclonal antibody that specifically ... has been demonstrated to be a key mediator ... cell disease.  Fast Track designation is intended to ...
Breaking Biology Technology:Permian Plastics LLC Celebrates 20 Years As Leading Manufacturer of Plastic Molds 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 3NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 4LABORIE adquiere Unisensor AG y Unisensor USA, Inc. 2FDA Grants Fast Track Designation to NKT Therapeutics' NKTT120 for the Treatment of Sickle Cell Disease 2
... NEW YORK, Nov. 29, 2011  Roche (SIX: RO, ROG; OTCQX: ... announced today a licensing agreement for PTC,s Spinal Muscular ... that causes muscle weakness. One in every 10,000 children ... no effective treatment. PTC Therapeutics, programme ...
... CHICAGO, Nov. 29, 2011 Sundberg , a leading ... appliance and HVAC parts, is kicking ... the opening of a new headquarters facility and two state-of-the-art ... in the development of two world-class, logistically centric warehouses: a ...
...   Bacterin International Holdings, Inc. (NYSE Amex: ... revolutionary bone graft material and antimicrobial coatings for medical ... for distribution in the U.S. and Canada of Jeil,s ... of orthopedic implants used in craniomaxillofacial procedures, including trauma ...
Cached Biology Technology:Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA) 2Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA) 3Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA) 4Sundberg Kicks Off National Expansion With Openings of New Headquarters, Logistically Centric Mega Warehouses 2Bacterin Signs Distribution Agreement with Jeil for 'LeForte Craniomaxillofacial System' 2Bacterin Signs Distribution Agreement with Jeil for 'LeForte Craniomaxillofacial System' 3Bacterin Signs Distribution Agreement with Jeil for 'LeForte Craniomaxillofacial System' 4
(Date:9/30/2014)... Ludwig-Maximilians-Universitaet (LMU) in Munich report that a new ... sensitive to chemotherapeutic drugs. They have also pinpointed ... target for anti-tumor agents. , Researchers led ... Sieber of the Technische Universitt Mnchen have identified ... new weapon in the fight against malignant tumors. ...
(Date:9/30/2014)... a suite of perilous threats in today,s ocean. ... climate change, fragile coral ecosystems are disappearing at ... some species of corals surrounding the island of ... in their tropical environment: coral guard-crabs. New research ... Marine Station scientist Seabird McKeon and the museum,s ...
(Date:9/29/2014)... September 29, 2014 -- Plants have a ... help the pants extract nutrients and defend against ... from contaminating fruits and vegetables. Now, scientist have ... inside of seeds; thus ensuring that sprouting plants ... the University of Notre Dame, presented their findings ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Plants prepackage beneficial microbes in their seeds 2
... Wiley & Sons, Inc., a global provider of content-enabled ... research; professional development; and education, in 2013. The titles ... or self-publication, and 14 new titles, of which eight ... with over 30 societies and associations. Included in ...
... Evolutionary Bioinformatics Laboratory at the University of Illinois in ... to probe the world of proteins for answers to ... are formed from chains of amino acids and fold ... crop sciences professor Gustavo Caetano-Anolls, very little is known ...
... AMHERST, Mass. For hundreds of years, naturalists ... an organism,s visible differences. But now, new genetic ... little, to no visible differences. In a ... Massachusetts Amherst and the American Museum of Natural ...
Cached Biology News:66 titles join Wiley's journal portfolio in 2013 2Untangling life's origins 2Untangling life's origins 3Researchers develop tools for discovering new species 2Researchers develop tools for discovering new species 3
... allows for rapid, convenient, and efficient native ... process utilizes a spin column to make ... concentration of proteins which were electro-eluted in ... ion exchangers, offering high binding capacity fo ...
... high-speed analytical techniques, the AutoTrace SPE is a powerful, high-throughput workstation dedicated specifically ... loading and elution steps for large volumes aqueous solution extractions (up to 2000ml's). ... ... ...
... clear polystyrene with frosted labeling surfaces, ... cell counting. 100% integrity tested. Linkage: ... product number, created to easily match ... availability yet, please order under the ...
Cell Culture Flask, nontreated polystyrene...
Biology Products: